Valuation : IceCure Medical Ltd

Market Cap 7.85M 0 6.74M 6.32M 5.77M 10.9M 748M 10.95M 74.81M 28.99M 378M 29.46M 28.82M 1.25B P/E 2026 *
-0.41x
P/E 2027 * -0.67x
Enterprise Value 7.85M 0 6.74M 6.32M 5.77M 10.9M 748M 10.95M 74.81M 28.99M 378M 29.46M 28.82M 1.25B EV / Sales 2026 *
1.83x
EV / Sales 2027 * 0.89x
Free-Float
54.2%
Yield 2026 *
-
Yield 2027 * -
08-24 Icecure Medical Ltd. Signs Exclusive Distribution Agreement with Scovas Medical for Prosense Cryoablation Systems in the Netherlands CI
08-20 IceCure Medical Receives IRB Approval to Commence ChoICE Study for ProSense Cryoablation in Breast Cancer CI
08-13 Icecure Medical Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation CI
08-12 IceCure Medical Ltd, Q2 2026 Earnings Call, Aug 12, 2026
08-12 IceCure Medical Ltd Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-11 IceCure Medical Ltd. Announces Board and Committee Changes, Effective August 14, 2026 CI
08-06 IceCure Medical Ltd. Adds Adventist Health Glendale As U.S. Clinical Site For Its Post-Marketing ChoICE Study For Low-Risk Breast Cancer Cryoablation Treatment CI
08-06 Icecure Medical Adds Adventist Health Glendale as First U.S. Clinical Site Able to Enroll Patients in the Choice Study for Prosense Cryoablation Treatment CI
07-27 IceCure Medical Kicks Off Post-Marketing ChoICE Study for ProSense Cryoablation in Low-Risk Breast Cancer Treatment at First U.S. Clinical Site CI
07-14 IceCure Medical Expands ProSense Cryoablation System Install Base and Clinical Adoption In The United States CI
07-06 IceCure Medical Highlights Expanding Commercial Adoption Of ProSense Cryoablation In Brazil Following FDA Clearance For Breast Cancer CI
06-26 IceCure Medical Files to Register Sale of 5.5 Million Shares by Armistice MT
06-23 IceCure Medical Ltd. Highlights Peer-Reviewed Journal Article Demonstrating ProSense Cryoablation Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer CI
Manager TitleAgeSince
Chief Executive Officer 65 01/09/2016
Director of Finance/CFO 50 17/05/2026
Chief Operating Officer 49 05/11/2025
Director TitleAgeSince
Director/Board Member 65 05/12/2017
Chairman 62 05/12/2017
Director/Board Member 57 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-6.22% - - 7.85M
-0.04%+0.90%+29.72%+16.14% 234B
+0.51%+0.09%+5.41%-17.36% 151B
-0.21%-1.36%-21.60%+22.53% 131B
-1.47%-3.05%-54.79%-11.02% 69.81B
-0.31%+0.67%+11.79%+18.95% 52.33B
-0.70%-2.19%-17.48%-14.89% 50.91B
+2.25%+0.17%+31.91%+30.56% 43.8B
+2.13%+3.09%+41.60%+48.23% 40.69B
+0.01%+2.20%-17.20%+44.23% 34B
Average +0.22%+0.04%+1.04%+15.26% 89.79B
Weighted average by Cap. +0.11%-0.04%+4.16%+10.36%

Financials

2026 *2027 *
Net sales 4.3M 0 3.69M 3.46M 3.16M 5.96M 410M 5.99M 40.95M 15.87M 207M 16.13M 15.78M 684M 8.8M 0 7.56M 7.09M 6.48M 12.22M 840M 12.28M 83.93M 32.53M 424M 33.05M 32.34M 1.4B
Net income -17.66M -0 -15.16M -14.22M -12.99M -24.52M -1.68B -24.64M -168M -65.24M -850M -66.3M -64.86M -2.81B -16.34M -0 -14.02M -13.16M -12.02M -22.68M -1.56B -22.79M -156M -60.36M -786M -61.34M -60.01M -2.6B
Net Debt - -
Logo IceCure Medical Ltd
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Employees
68
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-